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Persistent and Safe Blood Pressure Lowering Effects of Renal Artery
Denervation: Three Year Follow-up From the Symplicity HTN-2 Trial
Murray D. Esler1, Henry Krum2, Markus P. Schlaich3, Roland E. Schmieder4,
Michael Bohm5
1Baker IDI Heart and Diabetes Institute, Melbourne, Australia, 2Monash University,
Melbourne, Australia, 3Baker Heart and Diabetes Institute, Melbourne, Australia,
4University Hospital Erlangen-Nürnberg, Erlangen , Germany, 5Universitätsklinikum
des Saarlandes, Homburg, Saarland
Background: The Symplicity HTN-2 trial randomized subjects with treatment-
resistant hypertension to renal artery denervation (RDN) with the Symplicity renal
denervation system or no RDN while all subjects were maintained on a consistent
antihypertensive drug regimen (3 drugs including a diuretic). The 6 month primary
endpoint demonstrated a signiﬁcant reduction in blood pressure (BP) in the RDN
group with no change in the control group. Long-term follow-up is now ongoing to
conﬁrm the safety and sustained beneﬁt of RDN.
Methods: Following the 6 month primary endpoint control subjects were eligible to
crossover to RDN. All subjects will be followed for 3 years (30 months post-RDN for
crossover patients) to assess long-term effectiveness and safety of RDN.
Results: At baseline, 60% of crossover subjects were female and 35% of RDN
subjects were female; 30 % of the crossover subjects and 40% of the RDN subjects
had type 2 diabetes. BP was signiﬁcantly lower than baseline at each time point
(table). At 2 years post-RDN 70% of subjects had a systolic BP drop of 20 mm Hg.
Medication changes were not associated with changes in BP. The heart rate drop
observed after RDN may be due to central sympathetic inhibition from afferent nerve
ablation. Bradycardia requiring atropine occurred during RDN in 13% of subjects with
no sequelae. There was 1 case of transient acute renal failure and 2 deaths unrelated to
RDN at 2 years.Ofﬁce BP
(mm Hg) Initial RDN
Cross-over to
RDN
Heart Rate
(bpm) Initial RDN
Cross-over to
RDN
Pre-procedure
baseliney
(n¼52) (n¼37) Pre-procedure
baseliney
(n¼52) (n¼37)
Systolic BP 178.217.7 190.919.6 74.7  14.9 71.8  15.3
Diastolic BP 97.015.8 101.416.2
6 mo. D from
baseline
(n¼49) (n¼35) 6 mo. D from
baseline
(n¼49) (n¼35)
Systolic BP -31.7  23.1 -23.7  27.5 -4.9  10.2 -2.6  13.9
Diastolic BP -11.7  11.2 -8.4  12.1 p<0.01 P¼0.28
12 mo. D from
baseline
(n¼47) (n¼33) 12 mo. D from
baseline
(n¼47) (n¼33)
Systolic BP -28.1  24.9 -23.8  30.5 -5.0  9.0 -6.4  13.1
Diastolic BP -9.7  10.6 -9.99  12.4 p<0.01 p<0.01
24 mo D from
baseline
Systolic
(n¼40) (n¼26) 24 mo D from
baseline
(n¼40) (n¼25)
BP -28.87  21.6 -35.3 30.5 -4.3  12.3 –0.1  11.6
Diastolic BP -10.4  11.2 -12.8  11.4 p¼0.03 P¼0.97
p<0.01for all BP changes from baseline
yCrossover group pre-procedure baseline is at 6 months post randomizationConclusions: RDN with the Symplicity catheter consistently reduced BP over 2
years with no serious safety concerns. Data to 3 years will be available for
presentation.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-59
Longer term safety and efﬁcacy of sympathetic renal artery denervation using
a multi-electrode renal artery denervation catheter in patients with drug-
resistant hypertension: Eighteen month results of a ﬁrst-in-human, multicenter
study
Stephen Worthley1, Matthew Worthley2, Derek P. Chew3, Ajay R. Sinhal3,
Ian T. Meredith4, Yuvaraj Malaiapan5, Konstantinos P. Tsiouﬁs6,
Vasilios Papademetriou7
1Royal Adelaide Hospital, Adelaide, Australia, 2University of Adelaide, Adelaide, SA,
3Flinders Medical Centre, Adelaide, SA, 4Monash University, Melbourne, Australia,
5Monash Medical Centre, Clayton, Victoria, 6Hippokratio Hospital, Athens, Greece,
7Georgetown University, Washington DC, DC
Background: Drug-resistant hypertension is a growing problem around the world.
Percutaneous sympathetic renal artery denervation is emerging as an approach for the
treatment of patients who do not respond adequately to optimal medical therapy.
Single-tip electrode radiofrequency ablation catheters have been used to achieve
sympathetic ﬁber interruption through the renal artery wall. However, long-term
results from systems designed to create predetermined stereotactic lesion pattern have
not been reported. We investigated the safety and efﬁcacy of a multi-electrode catheter
ablation system (EnligHTN) developed by St. Jude Medical.
Methods: The EnligHTN renal denervation system has 4 electrodes attached on
a basket mounted at the tip of the catheter. The basket is collapsed and can be
expanded via an external mechanism once the catheter is placed in the desired location
of the renal artery. The electrodes are then sequentially activated to achieve the desired
lesion pattern. The basket is then pulled back and repositioned for a new set of lesions
in order to optimize renal artery denervation. The EnligHTN-I ﬁrst-in-human study
was designed to assess the safety and efﬁcacy of this multi-electrode ablation system
in patients with drug-resistant hypertension.
Results: A total of 46 patients (average age 6010yrs taking an average of 4.10.6
medications) were enrolled in this study. Bilateral renal nerve ablation was performed.
Average reductions (mmHg) of ofﬁce BP at 1, 3, 6 and 12 months were -28/10, -27/
10, -26/10 and -27/11 mmHg (p<0.001). At 12 months there were no signiﬁcant
changes in the estimated glomerular ﬁltration rate (from 87 to 86 mL/min/1.73m2) or
in serum creatinine (from 78 to 80 mmol/L), but cystatin C levels improved (from 1.14
at baseline to 0.91 mg/L at 12 months, (p<0.0001)) in addition to improvements in
urine albumin-to-creatinine ratio (from 169 at baseline to 117 mg/g at 12 months
(p<0.0003)). Eighteen month efﬁcacy and safety data will be presented at the
meeting.
Conclusions: We conclude this data demonstrates that the EnligHTN ablation system
continues to be safe and effective in the treatment of patients with drug-resistant
hypertension.
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Background: The Symplicity renal denervation system was designed to deliver
low-power radio frequency energy within the renal artery to ablate the surrounding
nerves and thereby lower blood pressure (BP) in hypertensive patients unresponsive to
pharmacologic therapy. Controlled clinical trials have shown the renal denervation
(RDN) procedure to be safe and effective in patients with treatment-resistant hyper-
tension. The Global SYMPLICITY Registry (GSR) is designed to further evaluate the
safety and effectiveness of RDN with the Symplicity Flex catheter in real world
patients with hypertension.
Methods: The GSR is a prospective, multicenter, single-arm registry with an intended
enrollment of 5000 patients at w200 sites worldwide. Adult patients with diseases
characterized by an increased sympathetic activity are enrolled. Data collected
includes ofﬁce-based and ambulatory BP measurements, change in antihypertensive
medications, renal function measures, and protocol-deﬁned safety events.
Results: There were 617 patients treated as of January 2013. Baseline patient char-
acteristics include mean age of 6013 years, 63% males, and 38% have type 2 dia-
betes. The mean renal artery length was 4314 mm with a mean diameter of 5.71.3
mm. Baseline ofﬁce BP was 16423/8916 mmHg, mean estimated glomerular
ﬁltration rate was 8053 ml/min/1.73m2 and patients were taking 4.41.3 different
classes of antihypertensive drugs. There were no major procedural complications;
arterial spasm occurred in 9% of patients and 2 pseudoaneurysms occurred. In patients
with a baseline BP >160 mmHg (150 mmHg for patients with diabetes) the mean BP
drop was -1722/-713 mmHg at 3 months (n¼247) and -1720/-812 mmHg at 6
months (n¼134) (p<0.001 for both). No new reports of vascular abnormalities were
reported, There was 1 death, 2 myocardial infarctions, 2 hypertensive events requiring
hospitalization and 1 new end-stage renal disease.
Conclusions: Current data from the GSR demonstrates that RDN can be safety
applied in a real world population and signiﬁcant BP drops from baseline wereacts/ORAL/Renal Denervation and Endovascular Intervention B19
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tation in October.
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Optimized External Focused Ultrasound for Renal Sympathetic Denervation –
Wave II trial
Petr Neuzil1, Robert J. Whitbourn2, Zdenek Starek3, Murray D. Esler4, Todd Brinton5,
Michael Gertner6
1Nemocnice na Homolce, Prague, Czech Republic, 2Cardiovascular Research Centre,
St. Vincent Hospital Melbourne, Melbourne, Australia, 3St. Anne’s University
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Australia, 5Stanford University, Stanford, California, 6Kona Medical, Inc, Bellevue,
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Background: We previously reported the results of the WAVE 1 trial for Renal
Sympathetic Denervation in twenty-four patients with refractory hypertension using
the Kona Surround Sound System. Six month results demonstrated a 27mmHg
reduction in systolic blood pressure in the study. This technology utilizes external
focused ultrasound navigated by a targeting catheter in the renal artery. The WAVE 1
protocol involved making 18 focused lesions over 12.6 minutes on each side. This
study (WAVE II) is evaluating the safety and efﬁcacy of an optimized treatment
protocol in which 14 focused lesions produced over 2.8 min on each side were utilized
to create sympathetic denervation.
Methods: Thirteen patients (8 men and 5 women; median age: 60 years), with
resistant arterial hypertension underwent bilateral externally focused ultrasound
utilizing a 5F intravascular catheter for targeting and tracking. Patients were on
a minimum of three antihypertensive medications. All treatments were performed in
patients under deep analgesic-sedation. The procedure was performed using the
2.8 min protocol for each side and targeting was directed to just proximal to the
bifurcation of the renal artery.
Results: During and after the procedure no serious complications were observed.
Unlike the WAVE I trial, only one of 13 patients complained of back pain following
the index procedure and this resolved within 4 days. To date, Eight patients reached
the 6-week follow up time point and Systolic BP decreased by 18 mmHg and diastolic
BP was unchanged.
Conclusions: The optimized externally focused ultrasound protocol was efﬁcient and
well tolerated. There were not serious adverse events reported and 6 weeks results for
eight patients were tracking similarly as patients treated in the WAVE I study which
ultimately resulting in a 27 mmHg reduction in systolic BP. Since externally focused
ultrasound can be performed safely, quickly, and effectively, the development of
a fully non-invasive system should offer even greater beneﬁts for patient care.
TCT-62
Preliminary Result of the Rapid Renal Sympathetic Denervation for Resistant
Hypertension Using the Maya Medical OneShot Ablation System (RAPID)
Study
Stefan Verheye1
1Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp,
Belgium
Background: Resistant hypertension remains a major health concern despite the
availability of effective pharmacological agents. Catheter-based renal sympathetic
denervation has emerged as a therapeutic option for patients with resistant hyper-
tension. Recent clinical reports show that ablation of the renal sympathetic nerves
using radiofrequency (RF) energy is safe and effective. The OneShot Renal
Denervation System (Covidien, Campbell, CA) is a balloon-based RF system using
a mounted spiral electrode with a unique feature of irrigation of the vessel wall-
during treatment. The non-compliant balloon is inﬂated under low pressure (1 atm)
in the renal artery, and the electrode delivers RF energy with a single 2-minute
treatment.
Methods: RAPID is a prospective, multicenter, single-arm study that enrolled 50
patients at 11 clinical sites in Europe and New Zealand. Patients were considered for
enrollment based on having an ofﬁce systolic blood pressure (SBP) 160 mmHg
despite treatment with a regimen three or more antihypertensive medications including
a diuretic.The follow-up period is at 1, 3, 6, 12, 24 and 36 months. The primary safety
endpoints include acute procedural safety, deﬁned as the overall rate of serious
adverse events (SAEs) and adverse device effects (ADEs) at discharge; and chronic
procedural safety, deﬁned as the overall rate of SAEs and ADEs at 6 months. The
primary effectiveness endpoint is the rate of ofﬁce systolic blood pressure reduction
> 10 mmHg at 6 months compared to baseline.
Results: Fifty patients were enrolled with a mean age of 63.0 years (58.0% male).
Patients were on a mean of 4.9 antihypertensive drugs at baseline. The mean baseline
ofﬁce systolic and diastolic blood pressure measurements were 181.6  20.8 and
95.5  15.5 mmHg, respectively.Results at 1 month showed a signiﬁcant reduction,
-17/-7 mmHg (p<0.0001 and p¼0.0008), in both systolic and diastolic blood pressure
measurements. An update of the ongoing study endpoint results will be presented at
TCT.
Conclusions: Preliminary results of the RAPID study demonstrate safe delivery of RF
energy for renal sympathetic denervation.B20 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jTCT-63
Drug-Coated Balloon (DCB) for Peripheral Arteries: Postdilatation of
Nitinolstents with DCB or plain balloon in the superﬁcial femoral artery –
Interim results of the Freeway Stent Study
Schulte Karl-Ludwig1, Josef Tacke2, Stefanie Stahnke3
1Charité Berlin, Vascular Center Berlin, Ev. Hospital Königin Elisabeth Herzberge,
Berlin, Germany, 2Klinikum Passau, Passau, Germany, 3Eurocor GmbH, Bonn,
Germany
Background: The restenosis rate of stents is still a major limitation of arterial
interventions. The Freeway Stent Study investigates the inhibition of restenosis by
Paclitaxel-eluting balloon dilatation post stent PTA versus stenting PTA with plain
balloon postdilatation in the treatment of the superﬁcial femoral artery. By this, the
Freeway Stent Study follows a new approach to potentially overcome the problem of
restenosis.
Methods: The Freeway Stent Study is a randomized, controlled multicenter trial
which is conducted in 15 centers in Germany and Austria. This study intends to enroll
200 patients being randomized in a 1:1 relation to either nitinol stenting followed by
drug-coated balloon FreewayTM (Eurocor GmbH) postdilatation or stenting with
plain balloon post dilatation. Primary endpoint is clinically driven target lesion
revascularization at 6 months. Further, secondary safety and efﬁcacy endpoints such
as late lumen loss at 6 months, patency rate and major adverse events are investigated.
Results: 150 patients have already been enrolled. More than 100 have completed the 6
months follow up. The results show a favorable outcome for the DCB arm in relation
to the TLR rate in this patient population which presented predominately with
occlusions. The results are supported by the clinical outcome of patency rate, ABI
index and presentation according to Rutherford.
Conclusions: In this trial the Freeway Paclitaxel-coated balloon is investigated in
a new approach to decrease the restenosis rate of stents in patients with stenting in the
SFA. Interim results will be provided to show that DCB might provide an advantage
also in these patients to overcome the existing limitations of peripheral artery disease
treatment.
TCT-64
Are Stent Grafts The Solution For In-Stent Restenosis After SFA Stenting
Koen Keirse1
1Heilig Hart Hospital, Tienen, Belgium
Background: Tackling in-stent restenosis (ISR) in the superﬁcial femoral artery
(SFA) has some challenges. To date literature review reveals only very limited data
on ISR in peripheral arteries. Current available treatments do not yield satisfactory
results, demonstrating the need of a treatment with a better outcome. The Viabahn
endoprosthesis with a heparin bioactive surface offers high ﬂexibility when
deployed in the SFA and the coating provides an enhanced hemocompatibility.
Methods: The RELINE trial is a prospective, randomized, multi-center, international,
controlled trial in which enrollment was allowed to continue until 80 patients meet the
eligibility criteria. Between June 2010 and February 2012, 100 patients were enrolled.
The ﬁrst primary endpoints is primary patency at 12 months, deﬁned as no evidence of
restenosis or occlusion within the originally treated lesion based on color-ﬂow duplex
ultrasound (CFDU) measuring a peak systolic velocity ratio 2.5 and without target
lesion revascularization (TLR) within 12 months. The second primary endpoint is the
proportion of subjects who experience serious device-related adverse events within 30
days post-procedure.
Results: The preliminary analysis is based on the intention-to-treat total of 100
patients. 47 (47.0%) patients were randomized to the VIABAHN ISR group and
53 (53.0%) patients were randomized to the POBA group. The demographic data
was comparable in both treatment groups. In the VIABAHN ISR group there were
34 (72.3%) men and the mean age was 67.34 (49-86) years. In the POBA group,
35 (66.0%) patients were male and the mean age was 69.26 (48-87) years. The
survival analysis shows a primary patency rate at 6 months of 94.4% for the
VIABAHN ISR group and 60.7% for the POBA group (p<0.001). Freedom of
TLR at 6 months is 94.3% in the VIABAHN ISR group and 60.4% in the POBA
group (p<0.001). These data are preliminary, indicated by the 24 patients at risk
in the VIABAHN ISR group and 14 patients at risk in the POBA group at 6
months.
Conclusions: With very good, but preliminary results, the full 12 months data anal-
yses are expected to be able to show a similar trend in patency outcome, which will
TCT-65
Directional Atherectomy is an Effective Treatment Option for Infrapopliteal
Lesions in Patients with Critical Limb Ischemia
Zeller Thomas1
1University Heart Centre Freiburg Bad Krozingen, Bad Krozingen, Germany
Background: The endovascular treatment of infrapoplitealarterial disease in patients
with critical limb ischemia (CLI) is complex and seldom studied. Directional athe-
rectomy (DA) revascularizes by removing the atherosclerotic plaque and minimizing
the need for balloon angioplasty and/or stenting. The DEFINITIVE LE study wasTCT Abstracts/ORAL/Renal Denervation and Endovascular Intervention
